RNA Atrium Therapeutics, Inc.
Fundamentals / CIK 0002093101 / USDAtrium Therapeutics, Inc. reported $264.0M in total assets through September 30, 2026 from SEC EDGAR filings.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open RNA in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2026-- Sep 30, 2026
-
Operating Income FY 2026-- Operating profit
-
Net Income FY 2026-- GAAP bottom line
-
Diluted EPS FY 2026-- Split-adjusted
-
Free Cash Flow FY 2026-- Operating CF less CapEx
-
Cash & ST Investments Sep 30, 2026$232.1M Total debt: $679K
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
| Income Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Revenue | $15.32M | $3.00M | $19.64M | $12.34M | $3.85M | $1.57M |
| Research & Development | $13.80M | $15.34M | $16.66M | $9.75M | $13.29M | $6.94M |
| Total Operating Expenses | $21.95M | $25.62M | $36.91M | $12.55M | $16.71M | $9.03M |
| Operating Income | -$6.63M | -$22.62M | -$17.28M | -$213K | -$12.86M | -$7.45M |
| EBITDA | -$6.28M | -$22.27M | -$17.13M | -$144K | -$12.79M | -$7.40M |
| Interest Income | $2.19M | $2.10M | -- | $0 | $0 | -- |
| Income Before Tax | -$4.27M | -- | -- | -$213K | -- | -- |
| Income Tax Expense | $0 | -- | -- | -$176K | -- | -- |
| Net Income | -$4.27M | -$20.19M | -$16.63M | -$37K | -$12.88M | -$7.45M |
| Basic EPS | -$0.25 | -$1.18 | -$0.97 | $0.00 | -$0.75 | -$0.44 |
| Diluted EPS | -$0.25 | -$1.18 | -$0.97 | $0.00 | -$0.75 | -$0.44 |
| Basic Shares Outstanding | 17.0M | 17.1M | 17.1M | 17.1M | 17.1M | 17.1M |
| Diluted Shares Outstanding | 17.0M | 17.1M | 17.1M | 17.1M | 17.1M | 17.1M |
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
| Cash & Cash Equivalents | $44.56M | $72.33M | $267.8M | $0 |
| Short-Term Investments | $187.5M | $191.6M | -- | $0 |
| Cash & Short-Term Investments | $232.1M | $263.9M | $267.8M | $0 |
| Other Current Assets | $2.13M | $6.33M | $138K | $1.31M |
| Total Current Assets | $258.1M | $275.1M | $285.6M | $2.85M |
| Property, Plant & Equipment, Net | $4.19M | $4.07M | $4.34M | $2.72M |
| Other Non-Current Assets | $1.12M | -- | -- | $0 |
| Total Non-Current Assets | $5.93M | $5.46M | $6.79M | $5.51M |
| Total Assets | $264.0M | $280.5M | $292.4M | $8.35M |
| Accounts Payable | $782K | $3.51M | $807K | $4.40M |
| Deferred Revenue (Current) | $9.45M | $9.04M | $9.34M | $21.64M |
| Total Current Liabilities | $24.66M | $31.51M | $21.91M | $41.80M |
| Deferred Revenue (Non-Current) | $32.92M | $33.65M | $36.35M | $28.69M |
| Other Non-Current Liabilities | $1.38M | $775K | $0 | $574K |
| Total Non-Current Liabilities | $34.30M | $34.43M | $36.35M | $29.27M |
| Total Liabilities | $58.97M | $65.94M | $58.26M | $71.07M |
| Total Debt (incl. Leases) | $679K | $1.68M | $2.68M | $3.67M |
| Common Stock | $16K | $16K | $16K | $0 |
| Retained Earnings | -$12.32M | -$8.06M | $12.13M | $0 |
| Accumulated Other Comp. Income | -$347K | -$235K | -- | $0 |
| Total Stockholders' Equity | $205.0M | $214.6M | $234.1M | -$62.71M |
| Total Equity | $205.0M | $214.6M | $234.1M | -$62.71M |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
| Cash Flow Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Net Income | -$4.27M | -$20.19M | -$16.63M | -$37K | -$12.88M | -$7.45M |
| Depreciation & Amortization | $352K | $343K | $151K | $69K | $79K | $53K |
| Stock-Based Compensation | $1.12M | $893K | $12.21M | $1.22M | $1.70M | $1.21M |
| Change in Receivables | -- | -- | -$15.00M | -- | -- | $0 |
| Change in Payables | -$2.73M | $2.71M | -$3.59M | $140K | -$258K | $37K |
| Operating Cash Flow | -$25.37M | -$3.93M | -$31.14M | $1.13M | -$11.91M | -$11.10M |
| Capital Expenditure | -$415K | -$36K | -$2.10M | -$300K | -$266K | $0 |
| Free Cash Flow | -$25.78M | -$3.96M | -$33.24M | $833K | -$12.17M | -$11.10M |
| Investing Cash Flow | $3.90M | -$191.6M | -$2.10M | -$300K | -$266K | $0 |
| Financing Cash Flow | -$6.30M | $0 | $301.5M | -$833K | $12.17M | $11.10M |
| Net Change in Cash | -$27.77M | -$195.5M | $268.3M | $0 | $0 | $0 |
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.
| Ratios & Growth | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Current Ratio | 10.46x | 8.73x | 13.04x | -- | -- | -- |
| Quick Ratio | 9.41x | 8.38x | 12.23x | -- | -- | -- |
| Debt to Equity | 0.00x | 0.01x | 0.01x | -- | -- | -- |
| Revenue Growth (YoY) | +24.2% | -21.9% | +1148.3% | -- | -- | -- |
| Operating Cash Flow Growth (YoY) | -2339.0% | -- | -- | -- | -- | -- |
| Free Cash Flow Growth (YoY) | -3195.2% | -- | -- | -- | -- | -- |